INTRODUCTION
Infective endocarditis is a relatively rare complication associated with a significant morbidity and mortality [1] . Its prevention has not decreased its incidence (3-7 per 100,000 person-years) [2] [3] [4] probably as a consequence of medical progress [5] .
In patients with congenital heart diseases (CHD), medical advances have modified the epidemiology of this population [6, 7] , considered at risk of developing infective endocarditis [8, 9] . The incidence of infective endocarditis in adults with CHD has been estimated as between 15 and 140 times that of the general population and represents 0.42-4% of hospitalizations [10, 11] .
In recent guidelines, infective endocarditis prevention strategies have restrained antibiotic prophylaxis and reinforced nonspecific hygiene measures [8, 12, 13] . For CHD patients, antibiotic prophylaxis before dental procedure is now recommended in five situations: prosthetic valve, previous infective endocarditis, unrepaired cyanotic CHD (including palliative shunts and conduits), completely repaired congenital heart defect with prosthetic material or device (whether placed using surgery or catheter intervention, during the first 6 months after the procedure), and repaired CHD with residual defects at the site or adjacent to the site of a prosthetic patch or prosthetic device [8, 12] .
Atrial septal defects (ASD) represent the second most frequent CHD (after ventricular septal defects), with a worldwide reported birth prevalence of 2.62 per 1,000 live births [14] . Ostium secundum ASD are predominant (80%) and eligible for catheter closure when the left-to-right shunt is significant, depending on the size of atrial septal rims [15] . Patent foramen ovale (PFO) is a small interatrial shunt caused by incomplete apposition of the septum primum to the septum secundum. Catheter closure is usually performed on carefully selected patients, as we need more data from randomized clinical trials comparing oral anticoagulants, antiplatelet therapy, and catheter occlusion [16, 17] .
Prosthetic infective endocarditis after ASD transcatheter closure is extremely rare, especially beyond the first few months after the procedure. We report one recent pediatric case of late infective endocarditis that occurred in an 8-year-old boy. We also reviewed the literature regarding infective endocarditis after atrial defect device closure.
METHOD
We searched three electronic databases on April 2016 (PubMed, EMBASE, and Web of Science) by using a combination of the terms "atrial septal defect" and "endocarditis." We also used the terms "catheter device," "device closure," "patent foramen ovale," "PFO," "ASD," "Amplatzer," "ASO," "STARFlex," "CardioSEAL," "infective endocarditis," and "interventional catheterization" in combination. The selection criteria were as follows: follow-up after ASD device closure, catheter devices complications, prosthetic endocarditis, and articles written in English. We did not set any restriction to study setting, era, or locale. Pediatric and adult patients were eligible. In title and abstract screening, two reviewers (P.A. and C.S.) independently reviewed articles identified by the search. Studies identified in title or abstract screening were included for full-text review.
CASE REPORT
At the age of five, our patient underwent transcatheter closure of ostium secundum ASD with the Amplatzer Atrial Septal Occluder Device (ASO; AGA Medical Corporation, Golden Valley, Minnesota). He was treated with antiplatelet therapy for 6 months postimplant (aspirin 5 mg/kg/day). Three years later, after a normal annual follow-up, he presented with prolonged fever, severe weight loss, and typical Janeway lesions on palms and soles. It is worthy noting that he had several untreated dental caries. Echocardiography showed a very thick pannus lining the left atrial disc of the prosthesis, with some mobile elements (Figure 1) .
The patient presented no neurological symptoms but an MRI showed several cerebral microemboli ( Figure 2 ). All blood cultures found Oxacillinsusceptible Staphylococcus aureus. The patient underwent intravenous antibiotic treatment with Gentamicin (2 weeks, 3 mg/kg/day) and Oxacillin (6 weeks, 200 mg/kg/day). Dental care was performed. Negative blood cultures were rapidly obtained. Echocardiography showed a decrease in the size of the pannus and the disappearance of mobile elements (Figure 1) .
After the end of medical treatment, a PET scan was performed and showed no activity. Cerebral lesions on the MRI remained stable. No immune deficiency was found. Three months after the end of antibiotic treatment, blood tests remained negative. After analyzing similar cases reported in the literature, we decided to remove the prosthesis surgically. After right atriotomy, under cardiopulmonary bypass and aortic crossclamping, the cardiac surgeon noticed a slightly incomplete endothelialization on the right atrial disc. The prosthesis was carefully removed from the right to the left. The left side was approximately similar to the right but some slight and nonspecific thickening (Figure 3 ) was clearly present. The surgeon observed no vegetation or any other noticeable lesion and closed the ASD with a pericardial patch. The bacteriological analysis of the prosthesis came back negative. After 2 years of follow-up, the patient's clinical course is favorable, including neurologically.
LITERATURE REVIEW
We selected seven ASD device follow-up studies [18] [19] [20] [21] [22] [23] [24] , one meta-analysis of percutaneous and surgical ASD closure [25] , and two FDA databases [26, 27] . We identified twenty-one cases of infective endocarditis following atrial septal device closure [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] (Table I) .
Three studies did not meet the selection criteria (fungal endocarditis following ventricular septal defect hybrid procedure [48] , atrial septal defect presenting with Brucella endocarditis [49] , and patch abcess after surgical closure of an atrial septal defect [50] ).
Infective endocarditis is commonly considered to be an exceptional event following percutaneous ASD device closure. No cases of endocarditis were reported in seven large series that included a total of 3568 patients who underwent ASD closure with mean follow-up ranging from 2 to 20 years [18] [19] [20] [21] [22] [23] [24] . In their review and meta-analysis of 1812 percutaneous versus 1270 surgical ASD closures, Butera et al. [25] only found one case of endocarditis in the "surgery" group. No case of endocarditis were reported in the FDA Maude database (United States Food and Drug Administration Time interval between device implantation and endocarditis. Abbreviations: ASDOS, atrial septal defect occlusion system (Sulzer Osypka, Rheinfelden, Germany); ASO, Amplatzer septal occluder; BC, blood culture; CHD, congenital heart disease; LA, left atrium; N/S, not specified; OS, ostium secundum atrial septal defect; PFO, patent foramen ovale; RA, right atrium; TEE, transoesophageal echocardiography; TTE, transthoracic echocardiography.
manufacturer and user facility device experience) among approximately 12,000 devices from AGA Medical Corporation (Amplatzer) and 8,950 devices from NMT Medical (STARflex, CardioSEAL) [26, 27] . Eight cases of infective endocarditis occurred after patent foramen ovale (PFO) percutaneous closure (1 ASDOS, 2 CardioSEAL, 2 ASO, 1 Helex, 1 CardioStar, 1 STARFlex). Twelve cases of ostium secundum ASD were closed with ASO devices (size 22-32 mm, size not specified for 7 patients). Including our pediatric patient, 7 cases of infective endocarditis occurred in children, after ostium secundum ASD device closure (mean age at procedure of 5 years). The absence of postprocedure residual shunt was only reported in six patients, but mostly not specified. Mean age when endocarditis occurred in the adult group was 53 years old. Diagnosis was made from 2 days to 12 years after the procedure. Thirteen cases can be considered to be late infective endocarditis (6 months or more after procedure). Five patients developed early symptoms following device implantation: 2 days after intervention for one patient (procedure carried out under antibiotics following a recent infection), and 2-3 months after the procedure for 3 patients. In each case, a history of recent infection before the procedure was noted.
Various clinical presentations included persistent fever, impaired general condition, chest pain, cerebral emboli, urinary tract infection, meningitis, petechiae, palpitations, and septic shock. A history of dental carries was never mentioned (besides our pediatric case).
Diagnosis was made by transesophageal echocardiography (TEE) and positive blood cultures in most cases, sometimes by transthoracic echocardiography (TTE) especially in the pediatric cases. Staphylococus aureus was found in most cases. Other reported germs were streptococcus, Bacillus pumilus, and Klebsiella pneumonia. Negative blood cultures occurred in four cases.
Most patients (n ¼ 18) underwent surgical removal of the device, usually after at least 2-3 weeks of antibiotics. All the patients received antibiotics for at least 6 weeks. A few patients were treated with antibiotics only. Endothelialization of the device was reported by surgeon as absent or incomplete in 8 cases, complete in 3 cases and not specified in 10 cases. Two adult patients died after surgery [28] (Table II) .
DISCUSSION
Mechanisms of infection after ASD device closure remain unclear. In many of these reported cases, it is difficult to know whether the introduction of bacteria occurred before, during, or after the catheter procedure. However, in some cases, patients with recent infections underwent a catheter procedure [30] . Even if preanesthetic blood tests are negative, we recommend postponing ASD closure when the patient presents with any recent clinical symptoms of infection.
In other reported cases of infective endocarditis, some invasive procedures were performed shortly after catheter occlusion, suggesting bacteremia following skin puncture. The risk for infective endocarditis might have therefore been underestimated [29] .
Some authors suggested that infection might have occurred before the end of neo-endothelialization, with seeding of microorganisms after the procedure, and development of thrombus and bacteremia. In animal studies, the neo-endothelium is supposed to completely recover the ASD prosthesis within a few weeks [51] . Therefore, the length of antiplatelet therapy and antibiotic prophylaxis of endocarditis has been arbitrarily recommended for 6 months after ASO implantation [12] .
These cases of infective endocarditis might therefore challenge the duration of endocarditis prophylaxis after transcatheter ASD closure. Recent guidelines on prevention, diagnosis, and treatment of infective endocarditis recommend good oral hygiene and regular dental care to reduce the risk of infection [8, 12] . However, in a recent survey, more than half of the pediatric cardiologists do not follow the American Heart Association 2007 guidelines in their practice [52] . Therefore, counseling for optimal oral health in patients at risk of infective endocarditis needs to be improved in current practice.
LIMITATIONS
This review is designed as a summary; therefore, no conclusions can be drawn.
CONCLUSION
Infective endocarditis is considered to be an exceptional event following percutaneous ASD device closure. However, 21 cases had previously been reported in the literature, besides our current pediatric case report. Specific infectious mechanisms remain unclear. Therefore, before ASD closure, recent infectious events should be investigated and, if suspected, catheter procedure should be postponed. As incomplete device endothelialization is impossible to detect in routine follow-up, it may be worth insisting on prevention of infection on a long-term, or even life-long, basis following ASD device closure. Moreover, oral health prevention probably needs to be reinforced.
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